Aurora Spine (ASG) Q2 2024 earnings summary

Executive summary

• Achieved $4.1 million in Q2 2024 revenue, marking the third consecutive quarter above $4 million and a 14.3% increase over Q2 2023, with 24% year-over-year growth.

• Net loss narrowed to $0.15 million from $0.482 million in Q2 2023, with EPS at $0.00.

• Achieved fourth consecutive quarter of positive EBITDA/EBITDAC, reaching $0.11 million in Q2 2024, a $269,182 improvement year-over-year.

• Strong demand in the pain market, especially for SiLO TFX and ZIP 51 implants, driven by targeted marketing, expanded sales force, and advanced training.

• Continued expansion into underserved markets and increased surgeon adoption through advanced training and onboarding.

Financial highlights

• Gross margin improved to 62.4% in Q2 2024 from 56.9% in Q2 2023, attributed to higher proprietary product sales and favorable pricing.

• Operating expenses rose to $2.74 million, mainly due to higher commissions, salary, and travel for sales force expansion.

• Operating cash flow was $0.348 million, reflecting effective working capital management.

• Six-month revenue reached $8.05 million, up from $6.48 million in 2023, with net loss reduced to $0.42 million from $1.145 million.

• Cash and equivalents at quarter end were $0.52 million, with total assets of $11.99 million.

Outlook and guidance

• Management targets a $5 million quarter and a $20 million annual run rate, aiming for net positive income in upcoming quarters.

• Confident in reaching profitability without needing to raise additional capital, supported by improved cash collections and cost controls.

• Ongoing expansion of the sales force and new product launches expected to drive further growth.

• Focused on innovation and clinical training to support adoption of ZIP and SiLO implants.